For decades, fatty liver disease, specifically metabolic dysfunction-associated steatotic liver disease (MASLD), and its more severe inflammatory form, metabolic dysfunction-associated…
Read More
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist
For decades, metabolic dysfunction-associated steatohepatitis (MASH), a more serious inflammatory form of fatty liver disease, remained a largely overlooked condition,…
Read More
Boehringer Ingelheim Eyes MASH as the Next Front for Survodutide, a GLP-1/Glucagon Receptor Dual Agonist
For decades, fatty liver disease, specifically its more severe inflammatory manifestation known as metabolic dysfunction-associated steatohepatitis (MASH), remained a significant…
Read More
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist
For decades, fatty liver disease, and its more severe inflammatory progression known as metabolic dysfunction-associated steatohepatitis (MASH), remained largely overlooked…
Read More
Immunai and Boehringer Ingelheim Forge Strategic Alliance to Uncover Novel T-Cell Targets in Oncology and Autoimmune Diseases
Immunai, a leading artificial intelligence (AI) company specializing in immune system analysis, and Boehringer Ingelheim, a global biopharmaceutical giant, have…
Read More
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist
Neeraja Balachander, who oversees Boehringer Ingelheim’s extensive cardio-renal-metabolic portfolio, articulated the company’s ambitious vision. “We have a program in MASH,…
Read More
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist.
For decades, metabolic dysfunction-associated steatohepatitis (MASH), the more severe inflammatory form of fatty liver disease, was a silent epidemic, often…
Read More
Boehringer Ingelheim Establishes Cutting-Edge AI and Machine Learning Hub in London to Accelerate Targeted Medicine Discovery
Boehringer Ingelheim has officially launched a new, state-of-the-art Artificial Intelligence (AI) and Machine Learning (ML) center in London’s King’s Cross,…
Read More
Boehringer Ingelheim and Zai Lab Forge Clinical Collaboration to Pioneer Novel Combination Therapy for Aggressive Lung Cancers
Boehringer Ingelheim and Zai Lab have announced a significant clinical collaboration aimed at investigating a dual delta-like ligand 3 (DLL3)-targeting…
Read MoreYOU MAY HAVE MISSED
